Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 3, 2012, Pages 681-684

  Gutiérrez Valencia, Alicia ^a   Martin Peña, Reyes ^a   Torres Cornejo, Almudena ^a   Ruiz Valderas, Rosa ^a   Castillo Ferrando, Juan R ^a   López Cortés, Luis F ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Antiretroviral treatment; Liquid chromatography; Mass spectrometry; Non nucleoside reverse transcriptase inhibitors

Indexed keywords

EMTRICITABINE; ETRAVIRINE; PROTEINASE INHIBITOR; RALTEGRAVIR; TENOFOVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRACELLULAR SPACE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; OPEN STUDY; OUTCOME ASSESSMENT; SEQUENTIAL ANALYSIS; TREATMENT DURATION;

ADULT; ANTI-HIV AGENTS; BLOOD CELLS; CHROMATOGRAPHY, LIQUID; FEMALE; HIV INFECTIONS; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PLASMA; PYRIDAZINES;

EID: 84856954577     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr534     Document Type: Article

References (10)

1. Andries K, Azijn H, Thielemans T et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48: 4680-6.
2. Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 29-38.
3. Lazzarin A, Campbell T, Clotet B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 39-48.
4. European Medicines Agency. Summary of Product Characteristics- Intelence. 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000900/WC500034180.pdf (4 November 2011, date last accessed).
5. Martin M, Del Cacho E, Codina C et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses 2008; 24: 1263-8.
6. Martinez E, Nelson M. Simplification of antiretroviral therapy with etravirine. AIDS Rev 2010; 12: 52-9.
7. Boffito M, Jackson A, Lamorde M et al. Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers. J Acquir Immune Defic Syndr 2009; 52: 222-7.
8. DeJesus E, Lalezari JP, Osiyemi O et al. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults. Antivir Ther 2010; 15: 711-20.
9. Fayet A, Beguin A, Zanolari B et al. A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: raltegravir, maraviroc, darunavir, and etravirine. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 1057-69.
10. Ter Heine R, Mulder JW, van Gorp EC et al. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients. Br J Clin Pharmacol 2010; 69: 475-83.